Seven Eight Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Seven Eight Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-69,791	Closed	-$1.04M	–	768
2019 Q2	$1.04M	Buy	+69,791	New	+$1.26M	0.05%	391
2018 Q3	–	Sell	-10,606	Closed	-$482K	–	743
2018 Q2	$482K	Buy	10,606 +1,300	+14%	+$63.2K	0.03%	363
2018 Q1	$491K	Buy	+9,306	New	+$543K	0.04%	268
2017 Q3	–	Sell	-8,917	Closed	-$835K	–	661
2017 Q2	$835K	Buy	+8,917	New	+$546K	0.12%	237
2017 Q1	–	Sell	-60	Closed	-$3K	–	719
2016 Q4	$3K	Buy	+60	New	+$2.11K	﹤0.01%	554
2015 Q1	–	Sell	-300	Closed	-$17K	–	694
2014 Q4	$17K	Buy	+300	New	+$15.8K	0.03%	367
2014 Q3	–	Sell	-200	Closed	-$8K	–	706
2014 Q2	$8K	Buy	+200	New	+$10.3K	0.01%	471

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Seven Eight Capital's CLVS Position: Q3 2019 in Review

Seven Eight Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 69,791 shares — an estimated $1.04M sold.

Seven Eight Capital first reported a position in CLVS in Q2 2014 and held it in 7 quarters. The position peaked at $1.04M in Q2 2019. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Seven Eight Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Seven Eight Capital sold 69,791 Clovis Oncology, Inc. shares in Q3 2019, an estimated $1.04M.
Seven Eight Capital first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 7 quarters.
Seven Eight Capital's Clovis Oncology, Inc. position peaked at $1.04M in Q2 2019.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Seven Eight Capital's 13F filing for Q3 2019, filed 14 Nov 2019.